Singapore, 23 March 2017 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has won the inaugural ‘BioSingapore Innovative Biomedical Company’ award.
The award, presented by BioSingapore, recognises Singapore-based biomedical companies that are at the forefront of innovation, and have demonstrated growth and sustainable business practices.
The award caps a year of significant developments for ASLAN as the Company prepares itself for a public listing on the Taipei Exchange later this year. In 2016, ASLAN closed a pre-IPO financing round of US$23 million. The Company forged new strategic collaborations with leading research institutions and commercial partners, including in-licensing deals to expand its existing pipeline to build a proprietary portfolio of innovative oncology programmes. ASLAN also received an orphan drug designation for its lead asset for gastric cancer.
Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals said, “My team and I are proud to be recognised with this award, which comes at a time when ASLAN is about to enter an exciting and pivotal new phase in its growth. The many new collaborations and rapid advancements in our pipeline would not have been possible without the immense work undertaken by my colleagues, or the support we have received from our partners and investors. We are grateful for this mark of confidence in all that ASLAN has achieved.”
The award was presented at the BioPharma Industry Awards ceremony on 22 March 2017, as part of the BioPharma Asia 2017 convention. This is the second consecutive year that ASLAN has been honoured at the awards. Last year, ASLAN was named ‘Asian Biotech of the Year’.
Ends
Media contact
Christine Wang
ASLAN Pharmaceuticals
Tel: +886 2 2757 6700
E-mail: investor@aslanpharma.com
Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com
The award, presented by BioSingapore, recognises Singapore-based biomedical companies that are at the forefront of innovation, and have demonstrated growth and sustainable business practices.
The award caps a year of significant developments for ASLAN as the Company prepares itself for a public listing on the Taipei Exchange later this year. In 2016, ASLAN closed a pre-IPO financing round of US$23 million. The Company forged new strategic collaborations with leading research institutions and commercial partners, including in-licensing deals to expand its existing pipeline to build a proprietary portfolio of innovative oncology programmes. ASLAN also received an orphan drug designation for its lead asset for gastric cancer.
Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals said, “My team and I are proud to be recognised with this award, which comes at a time when ASLAN is about to enter an exciting and pivotal new phase in its growth. The many new collaborations and rapid advancements in our pipeline would not have been possible without the immense work undertaken by my colleagues, or the support we have received from our partners and investors. We are grateful for this mark of confidence in all that ASLAN has achieved.”
The award was presented at the BioPharma Industry Awards ceremony on 22 March 2017, as part of the BioPharma Asia 2017 convention. This is the second consecutive year that ASLAN has been honoured at the awards. Last year, ASLAN was named ‘Asian Biotech of the Year’.
Ends
Media contact
Christine Wang
ASLAN Pharmaceuticals
Tel: +886 2 2757 6700
E-mail: investor@aslanpharma.com
Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com
